Figure 4
Mean change (±SE) from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR according to treatment duration in the PILLAR study.
Figure 4 | BMC Infectious Diseases
Mean change (±SE) from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR according to treatment duration in the PILLAR study.